Esbriet

Chemical Namepirfenidone
Dosage FormCapsule (oral; 267 mg); Tablet (oral; 267 mg, 801 mg)
Drug ClassMiscellaneous
SystemRespiratory
CompanyGenentech
Approval Year2014

Indication

  • For the treatment of idiopathic pulmonary fibrosis (IPF).
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Esbriet (pirfenidone) Prescribing Information.2022Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults.2022American Journal of Respiratory and Critical Care Medicine
German guideline for idiopathic pulmonary fibrosis - update on pharmacological therapies 2017.2018Pneumologie (Stuttgart, Germany)